Influence of Model-Predicted Rivaroxaban Exposure an Efficacy and Safety Outcomes in Patients With Acute Co

Therapeutic Advances in Cardiovascular Disease

13, 1753944719863641

DOI: 10.1177/1753944719863641

Citation Report

#	Article	IF	Citations
1	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology, 2020, 75, 3140-3147.	12.0	58
2	CYP2C19*17 May Increase the Risk of Death Among Patients With an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Pharmacogenomics and Personalized Medicine, 2020, 13, 29-37.	2.8	18
3	Practical Recommendations to Combine Small-Molecule Inhibitors and Direct Oral Anticoagulants in Patients With Nonsmall Cell Lung Cancer. European Respiratory Review, 2022, 31, 220004.	10.2	21
4	Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics, 2023, 15, 588.	7.5	25
5	Poor Correlation of Rivaroxaban Concentration With the Routine Coagulation Screening Test in Chinese Patients With Atrial Fibrillation. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	1
6	Non-Vitamin-K-Antagonist Oral Anticoagulants (NOACs) After Acute Myocardial Infarction: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, 2024, 1, CD014678.	6.9	7
7	Effect of Furmonertinib on the Pharmacokinetics of Rivaroxaban or Apixaban in Vivo. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2025, 1251, 124425.	2.6	2